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Evidence Synthesis for Decision Making 6:
Embedding Evidence Synthesis in
Probabilistic Cost-effectiveness Analysis
Sofia Dias, PhD, Alex J. Sutton, PhD, Nicky J. Welton, PhD, A. E. Ades, PhD
When multiple parameters are estimated from the same
synthesis model, it is likely that correlations will be
induced between them. Network meta-analysis (mixed
treatment comparisons) is one example where such corre-
lations occur, along with meta-regression and syntheses
involving multiple related outcomes. These correlations
may affect the uncertainty in incremental net benefit
when treatment options are compared in a probabilistic
decision model, and it is therefore essential that methods
are adopted that propagate the joint parameter uncer-
tainty, including correlation structure, through the cost-
effectiveness model. This tutorial paper sets out 4 generic
approaches to evidence synthesis that are compatible with
probabilistic cost-effectiveness analysis. The first is evi-
dence synthesis by Bayesian posterior estimation and pos-
terior sampling where other parameters of the cost-
effectiveness model can be incorporated into the same
software platform. Bayesian Markov chain Monte Carlo
simulation methods with WinBUGS software are the
most popular choice for this option. A second possibility
is to conduct evidence synthesis by Bayesian posterior
estimation and then export the posterior samples to
another package where other parameters are generated
and the cost-effectiveness model is evaluated. Frequentist
methods of parameter estimation followed by forward
Monte Carlo simulation from the maximum likelihood
estimates and their variance-covariance matrix
represent a third approach. A fourth option is bootstrap
resampling—a frequentist simulation approach to param-
eter uncertainty. This tutorial paper also provides
guidance on how to identify situations in which no corre-
lations exist and therefore simpler approaches can be
adopted. Software suitable for transferring data between
different packages, and software that provides a user-
friendly interface for integrated software platforms, offer-
ing investigators a flexible way of examining alternative
scenarios, are reviewed. Key words: cost-effectiveness
analysis; probabilistic sensitivity analysis; evidence syn-
thesis; network meta-analysis. (Med Decis Making
2013;33:671–678)
Probabilistic methods in decision analysis wereintroduced in the 1980s.1,2 Their defining fea-
ture is that they allow for a full expression of the
uncertainty in model parameters. There are 2 main
reasons for advocating probabilistic methods in
decision making. The first is that they can provide
a form of sensitivity analysis that allows investiga-
tors to easily see the joint impact of the uncertainty
in multiple parameters on the expected costs and
benefits and on decision uncertainty. For this rea-
son, use of these methods is often called probabilis-
tic sensitivity analysis. A second reason is that,
faced with uncertainty in the vector/matrix of model
parameters u, decision makers should choose the
decision option, D, that delivers the highest ex-
pected net benefit. In other words, the decision
maker selects decision D*, such that
D ¼Max
D
Eu½NBðD; uÞ: ð1Þ
This ‘‘expectation’’ requires an integration of the
net benefit function, NB(D,u) over the joint distribu-
tion of parameters u. There are a wide range of
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methods for achieving this integration, and the
appropriate choice of method depends on the alge-
braic structure of the net benefit function.
It must be emphasized that the expected net bene-
fit is not the same as the net benefit at the expected
value of the parameters, except in the cases where
net benefit is linear in all its parameters, and there
are no correlations between parameters. This is rela-
tively rare, for several reasons. First, most evidence
synthesis is performed on log or logit scales, while
the parameters of cost-effectiveness models tend to
be probabilities on the natural scale. The transforma-
tion is a nonlinear one. Second, many cost-effective-
ness analyses (CEAs) include Markov models. Here,
the net benefit functions include terms in powers of
transition probabilities, again introducing nonlinear-
ity. Third, modern methods of evidence synthesis
such as network meta-analysis, also known as mixed
treatment comparisons, generate estimates of several
treatment efficacy parameters from a common data
set, in most cases inducing correlations between
parameters. These correlations may have little or no
bearing on the expected net benefit of each interven-
tion option, but they will directly affect the
uncertainty in incremental net benefits between
interventions. Other synthesis techniques that esti-
matemore than 1 parameter from a single data set also
induce parameter correlation structures. Perhaps the
most important are meta-regression,3,4 multiple out-
come synthesis,5–9 and bivariate meta-analysis.10
It is therefore essential that software solutions are
adopted which ensure that the complex uncertainty
structure in parameter estimates is faithfully propa-
gated through the decision model.11 The main pur-
pose of this paper is to provide guidance on the
computational approaches that will deliver probabi-
listic cost-effectiveness analysis in any situation.
Not only is Monte Carlo (MC) simulation from the
joint parameter distribution the simplest way to eval-
uate the expected net benefit, but for any form of
model it also delivers other crucial tools of probabilis-
tic CEA, such as plots of the cost-effectiveness plane,
cost-effectiveness acceptability curves, and estimates
of the probability that a decision is cost-effective.12,13
MC simulation is also the easiest fully general
approach to analysis of the expected value of informa-
tion,14–16 unless the net benefit can be assumed to be
normally distributed.17 Probabilistic methods have
been recommended in a range of leading textbooks
and tutorial papers and are the preferred option for
submissions to reimbursement agencies such as the
National Institute for Health and Clinical Excellence
(NICE) in the UK.13 We therefore recommend MC
simulation-based approaches for all analyses, even
for strictly linear models.
We address the question of which computational
approaches correctly preserve the properties of the
evidence synthesis within a probabilistic CEA. No
advice is given on the relativemerits of cohortmodels
compared with individual patient simulation or on
how to choose the bestmodel. This paper is restricted
to providing guidance on how to implement the
model of choice.
We set out 4main generic options. These should be
considered the ‘‘default’’ approaches as theywill cor-
rectly propagate the uncertainty structure in the
evidence synthesis in any situation. These include
2 uses of Bayesian Markov chain Monte Carlo
(MCMC) methods and 2 frequentist methods, either
(1) sampling from a multivariate distribution of the
estimates and their variance-covariance (VCV) matri-
ces or (2) bootstrapping. Some guidance is provided
on how to identify situations in which there are no
correlations andwhere simpler methods, and awider
range of software, can be adopted. This article pro-
vides a brief summary of software tools that can be
used to help interface between different software,
and it reviews some recent developments in user-
friendly ‘‘front ends’’ to assist the integrated use of
multiple software platforms. These offer ways in
which investigators can conduct scenario analyses,
not just with individual parameters but also with dif-
ferent data sets or different synthesis models, and
quickly see the impact on cost-effectiveness results.
METHODS TO INCORPORATE SYNTHESIS
RESULTS IN PROBABILISTIC
COST-EFFECTIVENESS ANALYSIS
There are several ways in which the results of the
evidence synthesis can be incorporated into the prob-
abilistic CEA. Table 1 summarizes the methods and
the restrictions on their use.
Bayesian Posterior Simulation: One-Stage
Approach
When estimation of the synthesis parameters is via
sampling from a Bayesian posterior distribution of
the relevant parameters, this can be integrated with
the CEA as a single process within a single program-
ming package, in what has been referred to as ‘‘com-
prehensive decision analysis.’’18–20
Bayesian MCMC simulation,21 using WinBUGS,22
OpenBUGS,23 or otherMCMC packages, provides the
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obvious example. The advantage of this approach is
that it not only estimates a Bayesian posterior distri-
bution but also is simulation-based, so that its out-
puts are perfectly compatible with the MC sampling
approach that has become the standard modeling
method in so many areas of science. Samples from
the joint posterior distribution can be put directly
through the decision analysis, so that net benefit
and other outputs can be evaluated for each set
of parameter samples, without requirements for
assumptions about its distributional form. Distribu-
tions of additional parameters and costs can be read-
ily incorporated.
Development of MCMC algorithms and sampling
schemes is a specialized area of research. Although
users need not have a detailed knowledge of the pre-
cise working of MCMC software, a good understand-
ing of the fundamentals of Bayesian data analysis is
essential. For completeness it is worth mentioning
that a broad range of non-MCMC simulation-based
Bayesian updating schemes have also been pro-
posed, including the sample importance resampling
algorithm,24 Bayesian melding,25,26 and Bayesian
Monte Carlo.27 All these have the same properties
as Bayesian MCMC in that they all feature both
Bayesian estimation and sampling from joint poste-
rior distributions. The latter 2 were specifically
designed for evidence synthesis.
Bayesian Posterior Simulation: Two-Stage
Approach
If investigators have preferred software for CEA,
either general software packages such as R, STATA,
or SAS or spreadsheet or decision tree packages
such as EXCEL or TreeAGE, a further option is to
take the posterior samples from the Bayesian
MCMC, or other posterior sampling scheme, and
use them as input to the CEA package. This has the
same technical properties as the Bayesian 1-stage
approach since the full posterior distribution is pre-
served. From WinBUGS, the CODA output, which
lists all values generated from the full posterior distri-
bution, can be exported into a spreadsheet-based pro-
gram such as EXCEL, using BUS–BUGS Utility for
Spreadsheets.28 When the CODA output is used, it
is important that the correlations in the parameter
estimates are preserved. This is done by ensuring
that all parameter values are sampled from the same
MCMC iteration. If the CODA output is stored as
separate columns for each parameter with iteration
values along the rows, this would correspond to sam-
pling all the parameter values in 1 row, each time.
The CODA output can also be converted to the freely
available statistical software R29 for convergence
diagnostics, further analysis, and plotting using
add-on packages such as BOA–Bayesian Output
Analysis Program30 or CODA–Convergence Diagnos-
tics and Output Analysis.31
A potential advantage of a 2-stage approach arises
in cases where there is substantial autocorrelation
between successive MCMC samples. This can arise
inmany situations but usually depends on the statisti-
cal model, the way it is parameterized, and sparseness
of the data. The effect of high levels of autocorrelation
is to increase the degree of Monte Carlo error, with the
result that it may require hundreds of thousands,
rather than tens of thousands, of simulations before
stable estimates are obtained. A common practice in
decision modeling has been to ‘‘thin’’ the posterior
Table 1 Summary of Methods and Their Properties and Restrictions
Estimation Output to CEA Software Restrictions
Bayesian MCMC None: CEA within MCMC software None
Bayesian MCMC MCMC chains exported None
Bayesian MCMC Posterior means, variances,
correlations
None, but assumes multivariate
normality in posterior distribution
Bayesian MCMC Posterior means and variances Only suitable if no correlation between
parametersa
Estimation by non-Bayesian
(frequentist) methods
Parameter estimates and variance-
covariance matrix
None, but assumes multivariate
normality of treatment effect estimates
Estimation by non-Bayesian
(frequentist) methods
Parameter estimates and their
variances
Only suitable if no correlation between
parametersa
Estimation by non-Bayesian
(frequentist) methods
Bootstrap resampling None, but special methods are necessary
for sparse data
Note: CEA = cost-effectiveness analysis; MCMC = Markov chain Monte Carlo.
aUsers should ensure that the data structure and analysis methods do not imply correlations between parameters, before using these methods.
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sampling. For example, rather than store every poste-
rior sample from the MCMC process, one might store
every tenth or every twentieth. This will usually be
enough to reduce autocorrelation substantially, so
that the decision model can be run with, say, 25,000
samples from a thinned chain rather than with the
500,000 original samples. This is particularly relevant
for computationally expensive models.
Frequentist Estimation with Monte Carlo Sampling
If evidence synthesis can be performed using fre-
quentist software (which may use a variety of meth-
ods of estimation, including methods of moments,
iterative weighted least-squares, or (restricted) maxi-
mum likelihood [(RE)ML]), a 2-stage approach is also
possible. The first step is estimation, which produces
parameter estimates and their VCVmatrix. In the sec-
ond step, these are used to populate a multivariate
normal distribution that can be used for forward MC
sampling (in the same or in a different package) along
with the other CEA parameters.
Awide range of frequentist approaches to pair-wise
meta-analysis exist (see below).However, of particular
significance in CEA are the recently published mod-
ules in STATA and R that are capable to estimating
more complex models. mvmeta9 is a STATA routine
that fits the same kinds of network meta-analysis and
indirect comparison models that are described in the
Bayesian literature32,33 as well as fitting multiple out-
come models. A similar module has been written in
R,34 although in its current form this is a network
extension of ‘‘bivariate’’ meta-analysis10 in which the
true absolute (baseline) effects and relative treatment
effects in each trial are drawn from a bivariate normal
distribution. This is a slightly differentmodel from the
unrelated baselines models recommended in the
decision-making literature.32,33 However, it is perfectly
feasible to program unrelated baseline network meta-
analysis software in R, SAS, or any other platform.
In many cases, the use of frequentist estimates and
their VCV matrix with RE models is likely to produce
parameter distributions with a little less uncertainty,
because Bayesian methods take uncertainty in vari-
ance parameters into account. The extent of the differ-
ence is unlikely to be critical, although investigators
should always be sure that posterior distributions of
variance parameters are sensible. Similarly, the exist-
ing frequentist approaches are all based on normal
approximations to likelihoods for count data. This
can lead todifficultieswith sparse data, and especially
with zero cells.32,35
Frequentist Estimation with Bootstrapping
The final option of estimation and then bootstrap-
ping36 has beenused from time to time inCEA.37 In its
original form, bootstrapping is a technique in which
one generates a series of ‘‘new’’ data sets by repeat-
edly resampling with replacement from the original
data, each time producing a new set of parameters
estimates. This stream of estimates can then be trea-
ted in the same way as samples from a Bayesian pos-
terior distribution. However, this procedure is not
always straightforward, particularly with small sam-
ple sizes and zero cells.
Nonetheless, a verywide range of variant bootstrap
procedures are available that can mitigate these and
other problems. In the parametric bootstrap, for
example, a model is fitted to the data by maximum
likelihood and is then used to generate a series of
data sets with the same size and structure as the orig-
inal. The analysis procedure is applied to each of
these data sets to generate a stream of parameter val-
ues. Data analysis based on resampling is a rich area
with an extensive literature. Readers are referred to
other texts for further information.36,38,39
SIMPLER APPROACHES AND WHEN
TO USE THEM
When single efficacy parameters are of interest,
such as in simple pair-wise meta-analysis, and each
parameter in the CEA is sourced from a distinct and
independent source, simpler approaches may be
adopted. There are no correlations between parame-
ters and therefore no VCV matrix. The computing
task in this case is exactly the same as described in
the 2-stage frequentist approach described above,
but because the synthesis task is substantially less
complex, a far wider range of software is available
to carry it out. An estimate of the relative treatment
effect and its variance can be found by either using
specific meta-analysis software or implementing
meta-analysis routines in standard statistical soft-
ware packages. The effect measure and its variance
can, in a second stage, be used to populate a distribu-
tion for the appropriate parameter in any software
suitable for probabilistic decision analysis.
A systematic and comprehensive review of all soft-
ware options capable of evidence synthesis is beyond
the scope of this paper, but noteworthy options are
described below andmore detailed reviews and com-
parisons are available elsewhere.40–43
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Numerous stand-alone meta-analysis packages
have been developed over the years, but the following
probably include the most extensive and up-to-date
feature sets:
 Comprehensive meta-analysis (commercial)44
 Meta-Analyst (free)43
 MIX,45 which is an add-on to EXCEL (commercial and
free versions available)
 RevMan,46 which is the official software of the
Cochrane Collaboration (free)
 EXCEL (commercial), withwhich simplemeta-analysis
can be carried out with a small amount of
programming
In addition, although it would be possible to pro-
grammost standard meta-analysis models in any rea-
sonably powerful general statistics package, probably
the most extensive freely available software routines
that allowmeta-analysis to be conducted and numer-
ous graphical outputs to be produced are available for
STATA47 and for R, such as the meta48 and rmeta49
packages.
Indirect comparisons represent another evidence
structure that does not induce correlations between
efficacy parameters.33,50 Here again, separate synthe-
ses can be carried out for trials comparing treatments
A and B and trials comparing treatments A and C.
Then the estimates obtained and their variances can
be entered into the simulation package used for
CEA, and the relative cost-effectiveness of A, B, and
C can be readily determined because covariances
are not involved. Although this is an acceptable
approach in principle, the BayesianMCMC approach
to indirect comparisons32,33 may be preferable in
cases in which 1 or more of the pair-wise compari-
sons is represented by a very small number of trials.
This is because MCMC has the flexibility to allow
‘‘shared variance’’ random effects (RE) models,32
whereas with existing frequentist methods it may be
necessary to have some estimates from random and
others from fixed-effects models, which not only is
a less natural solution but also runs counter to the
mathematical relationships between variances that
must hold in models in which all relative treatment
effects are internally consistent.51 There is, however,
nothing to prevent shared variancemodels being pro-
grammed in frequentist packages.
It is worth noting for completeness that certain
extensions of pair-wise or network meta-analysis
will induce correlations, and in these cases it would
be prudent to use 1 of the 4 fully general methods
above. One of these is meta-regression52 in which
the size of the relative effect depends on a covari-
ate.4,53 This is essentially a model with terms for
intercept and slope where these parameters will be
correlated unless the model is parameterized to
make them orthogonal. Another extension concerns
multiple outcomes. Very frequently, different trials
report different outcomes, or different combinations
of outcomes, at different times or combinations of
times, in different ways or combinations of ways.
Elsewhere54,55 we have advocated the use ofmethods
that effectively model the relationships between the
outcomes, in order to strengthen inference on the
treatment effects.5,56–58 This invariably induces cor-
relations between outcome parameters and between
outcome and treatment effect estimates. Similarly,
synthesis methods based on the bivariatemeta-analy-
sis model10 inevitably generate correlations between
treatment and control success rates.
The correlations induced by meta-regression or
by multiple outcome synthesis will usually have
less impact on incremental net-benefit than the
between-treatment effect correlations induced by
network meta-analysis or by the bivariate model for
meta-analysis. They will, however, affect joint
parameter uncertainty in other, and possibly com-
plex, ways, and it is prudent to use 1 of the 4 generic
approaches to propagating the joint parameter uncer-
tainty into the CEA model.
USE OF MULTIPLE SOFTWARE PLATFORMS
In recent years, interfaces have become available
that let different software applications communicate
with each other. These facilities allow for the integra-
tion of the components of a CEA that may have been
conducted in different packages. The motivations
and advantages of an integrated approach across soft-
ware applications are potentially multifaceted. First,
such an approach allows multidisciplinary teams
who have different software skills and preferences
to produce an integrated analysis. For example,
statisticians may wish to use general statistical soft-
ware, whereas decision modelers may wish to use
EXCEL or specific decision modeling software. This
approach also allows the best software for each com-
ponent of the analysis to be used, therefore producing
an ‘‘optimal’’ mix. For example, if a network meta-
analysis is required, WinBUGS may be the best soft-
ware to use, but it has limited graphical capabilities.
Therefore, it may be desirable to present the results of
the synthesis in a package with advanced graphical
capability such as R. Furthermore, the original data
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set may have been prepared in spreadsheet software
such as EXCEL. Although use of multiple pieces of
software to conduct different components of the anal-
ysis is common historically, few have been inte-
grated. Once a model has been set up within an
integrated system, it is, of course, particularly easy
to update.
This approach is also useful when updating
amodel that has already been constructed in a partic-
ular software: If, for example, the CEA is already set
up in Excel but a new evidence synthesis needs to
be carried out in R or WinBUGS, the packages can
be made to communicate directly, facilitating the
analysis and any future updates.
Communication Between Software Packages
The simplest formof communication between soft-
ware packages is to allow the transfer of data between
them. To facilitate communication, transparency,
and future data updates, it is good practice to keep
all data collected for the analysis, including all anno-
tations and details of any corrections, in a single file,
for example, an EXCEL workbook with multiple
worksheets. If the analysis is to be carried out inWin-
BUGS, data columns can be copied directly from
spreadsheet software into WinBUGS and pasted by
selecting Paste Special from the WinBUGS Edit
menu and choosing the Plain text option. Alterna-
tively, XL2BUGS59 is an EXCEL add-in that converts
EXCEL data into WinBUGS vector format, and
BAUW60 converts data in text format into WinBUGS
vector or matrix format.
If data are stored in R, R2WinBUGS61 can be used
to convert R objects into WinBUGS list data using
the bugs.data function.
See http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/
remote14.shtml for details on software capable of com-
municating with WinBUGS.
Integrated Use of Software Platforms
Integrated platforms reduce the need to copy data
and intermediate results from one screen/system to
another and thereby reduce the risk of transcription
errors. Further advantages of integrating the analysis
(which also exist if the Bayesian 1-stage approach is
conducted, since in that approach the analysis is inte-
grated by definition) include facilitating the modifi-
cation and updating of any aspect of the analysis,
conducting sensitivity analyses, and, more generally,
promoting transparency. For example, if a new trial is
reported that is to be added to the evidence synthesis,
then in an integrated approach the CEA would auto-
matically be updated. This goes someway to ensuring
that the appropriate uncertainty is propagated
through to the decision model. Different software
can be used to fully integrate data input, analysis,
and the display of results using multiple packages,
into a single step. If part of this integrated approach
is the inclusion of a user-friendly interface, this can
also make the exploration of the synthesis and CEA
accessible to nontechnical experts, including clinical
experts and even decision makers themselves, allow-
ing them to interrogate the analysis. To this end,
a Transparent Interactive Decision Interrogator
(TIDI),62 which integrated syntheses conducted in
WinBUGS with graphical displays and the decision
model conducted in R and a ‘‘point and click’’ inter-
face in EXCEL, was developed for a recent Single
Technology Appraisal at NICE. This pilot ‘‘proof of
concept’’ initiative allowedmembers of the appraisal
committee to request reruns of the CEA using alterna-
tive parameter distributions and synthesis models in
real time in the committee meetings.62
Several (freely available) code routines have been
developed for commonly used packages in health
technology assessment that allow them to communi-
cate with other packages, and these can be used in
the creation of integrated analyses. For example,
RExcel,63 an add-on to EXCEL, provides communica-
tion between EXCEL and R, and R2WinBUGS is one
of several packages that allow the user to controlWin-
BUGS through R. Thus, if both of these linking pack-
ages are used in combination, then WinBUGS can be
controlled through EXCEL (via R), and a Visual Basic
interface can be written in EXCEL to facilitate this
(which is the software setup used in the TIDI project
described above). Similar control of WinBUGS
through STATA64 and several other packages is also
possible, as is the embedding of OpenBUGS in R
through rbugs65 and the linking of many other pack-
ages to each other.
DISCUSSION
A number of previous authors have discussed
the role of parameter uncertainty in CEA and
the need for methods that appropriately propagate
parameter uncertainty through the model to the deci-
sion.12,16,18–20 This tutorial paper reviews the implica-
tions for choice of computational approaches in the
context of evidence synthesis. Our general conclusion
is that where the synthesis involves a network meta-
analysis, or other methods that induce parameter
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correlations, Bayesian MCMC methods of synthesis
are likely to be the most convenient because the full
joint posterior uncertainty in parameters can be easily
propagated through the decision model in a single
step.However, frequentist solutions are also available.
We recommend that where multiple software plat-
forms are used, for example, to store data, to carry out
the synthesis, and to run CEAs, an integrated
approach is taken,where the different platforms com-
municate with each other. This will avoid transcrip-
tion errors and allow for easy and immediate update
of results. User-friendly front-ends on integrated plat-
forms give decision makers the ability to interrogate
models more easily.
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